Latigo Biotherapeutics, Inc. LTGO
12.60 USD -0.41 (-3.15%)
At closeNov 6, 2026, 5:37 PM EST
12.30 -0.30 -2.38%
After hours · Nov 6, 5:37 PM ET
12.11 Day range 15.95
12.60 52-week range 25.00
- YTD
- -30.96%
- 1 year
- -30.96%
News
defenseworld.net Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the firm,…
benzinga.com Latigo Biotherapeutics Q3 EPS $(0.55) Beats $(0.58) Estimate Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.58) by 5.17 percent. This is a 98.14 percent increase over losses…
globenewswire.com Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027
globenewswire.com Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and…
globenewswire.com Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain…
benzinga.com Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company…
benzinga.com Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners analyst David Risinger initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Outperform rating and announces Price Target of $36.
benzinga.com Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.
benzinga.com Guggenheim Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.- benzinga.com Reported Earlier, Latigo Biotherapeutics Files To Sell Up To 16M IPO Shares Priced At $16-$18 Per Share This is an initial public offering of shares of common stock of Latigo Biotherapeutics, Inc. We are offering 16,000,000 shares of our common stock to be sold in this offering.Prior to this offering,…